Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 2: Radiolabeled Probes

John C. Stendahl†1,2 and Albert J. Sinusas†1–3

†Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut; ‡Yale Translational Research Imaging Center, Yale University School of Medicine, New Haven, Connecticut; and 3Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut

Nanoparticulate imaging agents and therapeutics have proven to be valuable tools in preclinical cardiovascular disease research. Because of their distinct properties and significant functional versatility, nanoparticulate imaging agents afford certain capabilities that are typically not provided by traditional small molecule agents. This review is the second in a two-part series covering nanoparticulate imaging agents and theranostics. It highlights current examples of radiolabeled nanoparticle probes in preclinical cardiovascular research and demonstrates their utility in applications such as blood pool imaging and molecular imaging of ischemia, angiogenesis, atherosclerosis, and inflammation. These agents provide valuable insight into the molecular and cellular mechanisms of cardiovascular disease and illustrate both the limitations and the significant potential of nanoparticles in diagnostic and therapeutic applications. Further technologic development to improve performance, address safety concerns, and fulfill regulatory obligations is required for clinical translation of these emergent technologies.

Key Words: nanoparticles; cardiovascular disease; PET; SPECT; molecular imaging

J Nucl Med 2015; 56:1637–1641
DOI: 10.2967/jnumed.115.164145

Nanoparticles have garnered significant interest as agents for cardiovascular imaging and therapeutic delivery. Nanoparticulate imaging agents typically demonstrate pharmacokinetic and biodistribution behavior different from that of small molecules and provide flexible platforms for integration of multiple functional entities, including targeting ligands, therapeutics, and/or multiple types of contrast materials. Importantly, nanoparticulate imaging agents are also capable of amplifying signals by delivering large volumes of contrast materials in concentrated packages. Despite these intriguing attributes, nanoparticulate imaging agents have thus far attained only limited clinical use and require additional development to overcome various functional limitations and safety concerns.

This review is the second in a two-part series covering nanoparticulate imaging agents and theranostics. It describes current examples of radiolabeled nanoparticle probes for PET and SPECT and highlights their utility in preclinical applications such as blood pool imaging and molecular imaging of ischemia, angiogenesis, atherosclerosis, and inflammation (Table 1). These agents provide valuable insight into the molecular and cellular mechanisms of cardiovascular disease and illustrate both the limitations and the significant potential of nanoparticles in diagnostic and therapeutic applications. Nanoparticle-based cardiovascular imaging via other modalities such as CT and MR has previously been reviewed in more detail elsewhere (1–4).

ISCHEMIA

Radiolabeled nanoparticles have been used to detect and characterize ischemic and infarcted tissue and to deliver relevant therapeutics. Although perfusion is reduced under conditions of ischemia and infarction, the associated vascular injury results in higher permeability than healthy tissue and allows for passive nanoparticle targeting via the enhanced permeability and retention effect. Lukyanov et al. demonstrated this passively targeted delivery strategy by showing increased uptake of 111In-labeled polymeric micelles in infarcted rabbit myocardium (5). In a separate study, 99mTc labeling was used to monitor retention of chitosan nanoparticles delivered by direct injection into ischemic myocardium (6). Similar, unlabeled, chitosan particles containing vascular endothelial growth factor were shown to increase perfusion to the ischemic tissue 1 wk after administration. Passively targeted delivery of therapeutics via nanoparticles has also been demonstrated in the ischemic brain, where 18F-labeled liposomes containing hemoglobin were shown to preferentially deposit in the ischemic zone of a middle cerebral artery thrombosis model despite very low perfusion levels (7).

ANGIOGENESIS

Radiolabeled nanoparticles have also been used for targeted molecular detection and characterization of new
<table>
<thead>
<tr>
<th>Imaging target</th>
<th>Particle type</th>
<th>Mean diameter</th>
<th>Targeting strategy</th>
<th>Labeling agent</th>
<th>Imaging modality</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ischemic myocardium</td>
<td>Polymeric micelles</td>
<td>7–20 nm</td>
<td>Passive</td>
<td>$^{111}$In</td>
<td>$\gamma$-camera</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Chitosan nanoparticles</td>
<td>100–150 nm</td>
<td>Passive</td>
<td>$^{99m}$Tc</td>
<td>ARG</td>
<td>6</td>
</tr>
<tr>
<td>Ischemic brain</td>
<td>Liposomes</td>
<td>210 nm</td>
<td>Passive</td>
<td>$^{18}$F</td>
<td>PET</td>
<td>7</td>
</tr>
<tr>
<td>Angiogenesis</td>
<td>Dendrimers</td>
<td>12 nm (prelabeling)</td>
<td>RGD peptide (binds $\alpha_v\beta_3$)</td>
<td>$^{76}$Br</td>
<td>PET/CT</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Comblike polymeric nanoparticles</td>
<td>22 nm</td>
<td>C-type atrial natriuretic factor</td>
<td>$^{64}$Cu</td>
<td>PET/CT</td>
<td>14</td>
</tr>
<tr>
<td>Gold nanoparticles</td>
<td></td>
<td>22 nm</td>
<td>RGD peptide (binds $\alpha_v\beta_3$)</td>
<td>$^{99m}$Tc, gold</td>
<td>SPECT/CT</td>
<td>10</td>
</tr>
<tr>
<td>Perfluorocarbon emulsion</td>
<td></td>
<td>270 nm</td>
<td>Nonpeptide $\alpha_v\beta_3$ antagonist</td>
<td>$^{99m}$Tc, $\text{Gd}^{3+}$, fluorophores</td>
<td>SPECT/CT/MR</td>
<td>11</td>
</tr>
<tr>
<td>Single-walled carbon nanotubes</td>
<td></td>
<td>1–5 × 100–300 nm</td>
<td>RGD peptide (binds $\alpha_v\beta_3$)</td>
<td>$^{64}$Cu, carbon nanotubes</td>
<td>PET, Raman spectroscopy (ex vivo)</td>
<td>12</td>
</tr>
<tr>
<td>Polymer-coated UCNPs (NaGdF$_4$: Yb$^{3+}$/Er$^{3+}$)</td>
<td></td>
<td>32 nm</td>
<td>RGD peptide (binds $\alpha_v\beta_3$)</td>
<td>$^{124}$I, UCNP</td>
<td>PET/MR, upconversion luminescence (ex vivo)</td>
<td>13</td>
</tr>
<tr>
<td>Blood pool</td>
<td>Dendrimers</td>
<td>12 nm</td>
<td>Passive</td>
<td>$^{99m}$Tc, TIBA</td>
<td>SPECT/CT</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>Cross-linked dextran shells/iron oxide cores</td>
<td>20 nm (base particle)</td>
<td>Passive</td>
<td>$^{18}$F, iron oxide, fluorophores</td>
<td>PET/CT/MR, fluorescence (ex vivo)</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>Core-shell star copolymers</td>
<td>25–70 nm</td>
<td>Passive</td>
<td>$^{64}$Cu</td>
<td>PET/CT</td>
<td>17</td>
</tr>
<tr>
<td>Atheromata (intraplaque inflammation)</td>
<td>Dendrimers</td>
<td>NA</td>
<td>LyP-1 peptide (binds macrophages)</td>
<td>$^{64}$Cu, fluorophores</td>
<td>PET/CT, fluorescence (ex vivo)</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Comblike polymer nanoparticles</td>
<td>15 nm</td>
<td>DAPTA (modified peptide, binds chemokine receptor-5)</td>
<td>$^{64}$Cu</td>
<td>PET/CT</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>Dextran nanoparticles</td>
<td>13 nm</td>
<td>Passive</td>
<td>$^{89}$Zr, fluorophores</td>
<td>PET/MR, ARG, fluorescence (ex vivo)</td>
<td>26</td>
</tr>
<tr>
<td>Cardiac allografts (graft inflammation)</td>
<td>Cross-linked dextran shells/iron oxide cores</td>
<td>20 nm</td>
<td>Passive</td>
<td>$^{64}$Cu, iron oxide, fluorophores</td>
<td>PET/CT, ARG, fluorescence (ex vivo)</td>
<td>29</td>
</tr>
<tr>
<td>Aortic aneurysms (mural inflammation)</td>
<td>Cross-linked dextran shells/iron oxide cores</td>
<td>20 nm (base particle)</td>
<td>Passive</td>
<td>$^{18}$F, iron oxide, fluorophores</td>
<td>PET/CT, ARG, fluorescence (ex vivo)</td>
<td>30</td>
</tr>
</tbody>
</table>

UCNP = upconversion nanophosphor; TIBA = 2,3,5-triodobenzoic acid; LDL = low-density lipoprotein; HDL = high-density lipoprotein; QD = quantum dot; NA = not available; ARG = autoradiography.
microvessels formed by angiogenesis. Potential clinical applications of angiogenesis imaging within the cardiovascular system include characterization of ischemia-induced angiogenesis and detection of intraplaque angiogenesis that predisposes to plaque rupture. The most established molecular target for angiogenesis is the αβ3 integrin, a heterodimeric transmembrane protein that is expressed on many cell types but differentially upregulated on proliferating endothelial cells (8). Nanoparticles targeted toward αβ3 integrins are well suited for angiogenesis imaging because they can limit signals from nonangiogenic αβ3 binding through multivalent ligand presentation and size-based vascular compartment confinement. Almutairi et al. successfully used 79Br-labeled multivalent dendrimers with αβ3-targeted peptides for PET/CT detection of angiogenesis in a murine model of hind limb ischemia (Fig. 1) (9). The power of presenting multiple αβ3-binding epitopes on a single dendrimer surface is demonstrated by the fact that the multivalent dendrimers exhibited a 50-fold enhancement in αβ3 binding affinity compared with monovalent free peptides. A variety of other types of nanoparticle platforms have been used for αβ3-mediated nuclear angiogenesis imaging, including gold particles (10), perfluorocarbon emulsions (11), carbon nanotubes (12), and lanthanide upconversion nanophosphors (13). Another potential molecular target for angiogenesis imaging is natriuretic peptide receptor C, which was targeted with a novel comblike polymeric nanoparticle functionalized with C-type atrial natriuretic factor fragments and labeled with 64Cu for PET imaging (14). This natriuretic peptide receptor C–targeted nanoparticle probe was used to noninvasively detect angiogenesis in an established murine model of hind limb ischemia.

BLOOD POOL IMAGING

Nanoparticles are also potentially useful as blood pool imaging agents because they can be designed for extended circulation with minimal extravasation into the surrounding tissue. Examples of nanoparticulate blood pool agents in nuclear imaging include multimodal dendrimers for SPECT/CT (15), multimodal cross-linked dextran iron oxide agents for PET/CT and PET/MR (16), and core-shell star copolymers for PET (17). The long circulation times of these particles are primarily attributable to their intermediate sizes and surface functionalization with polyethylene glycol moieties. These and other nanoparticulate agents may be useful for detection and characterization of ischemic heart and peripheral vascular diseases, including those related to microvascular dysfunction.

Given their capacity for extended circulation times, nanoparticulate blood pool agents are also potentially useful for defining vascular and cardiac structures. For example, nanoparticulate CT blood pool agents could be used with cine CT imaging for evaluation of the endocardial and epicardial surfaces. The use of this technique in combination with myocardial radiotracers in hybrid SPECT/CT or PET/CT imaging could allow for absolute radiotracer quantification with incorporation of partial-volume corrections for regional differences in wall thickness. Long-circulating nanoparticulate agents are also especially useful in small-animal SPECT/CT and PET/CT blood pool imaging, where CT images may be acquired over periods of...
several minutes without the substantial clearance that occurs with conventional small molecule CT contrast agents (15).

Nanoparticulate SPECT and CT contrast agents that remain in the vascular compartment for extended periods could also be used to evaluate the myocardial microcirculation, which is the primary determinant of intramyocardial blood volume. Conventional small molecule contrast agents tend to overestimate intramyocardial blood volume because of significant first-pass myocardial extraction (18). Quantitative analysis of myocardial blood flow could also be accomplished via kinetic modeling of purely intravascular nanoparticle CT contrast agents imaged via high-resolution dynamic cine CT (18).

ATHEROSCLEROSIS

Radiolabeled nanoparticles are well suited for detection and characterization of atherosclerotic lesions because their depth of tissue penetration typically does not exceed lesion thicknesses. Radiolabeled lipoprotein nanoparticles such as high- and low-density lipoproteins have been used since the 1980s to monitor lipoprotein particle circulation and lipid uptake in atheromatous lesions (19–21). Endogenous high-density lipo-

protein particles have dimensions on the order of 5–15 nm and are favorably suited for vascular imaging applications because of the ease with which they can be isolated and radiolabeled and their intrinsic uptake in atherosclerotic lesions. Since initial studies nearly 30 y ago, numerous advances have been made, including the development of particles with synthetic or reconstituted lipoprotein shells that are designed for multimodal imaging and therapeutic delivery (22). Lipoprotein nanoparticles have also been used extensively in studies involving nonnuclear imaging modalities such as MR; a review of this literature is available elsewhere (23).

Radiolabeled nanoparticles have also played significant roles in recent efforts to characterize intraplaque inflammation, which can induce thinning of fibrous caps on lesions and make them vulnerable to rupture. Nanoparticles targeted toward inflammatory cells have proven to be effective agents for detecting intraplaque inflammation and may provide ideal substrates for delivering Interventional payloads to stabilize plaques before they rupture and cause serious vascular events. Recent examples of nanoparticle-targeted intraplaque inflammatory cell imaging include 64Cu-labeled dendrimers targeted toward macrophages with LyP-1 peptides (PET/CT) (24), 64Cu-labeled synthetic polymer particles targeted toward chemokine receptor 5 on monocytes (PET/CT) (25), and 89Zr-labeled dextran nanoparticles passively targeted toward intraplaque monocytes and macrophages (PET/MR) (Fig. 3) (26). In this last case, separate lipid nanoparticles containing small interfering RNA to silence chemokine receptor 2, a receptor involved in recruitment of inflammatory monocytes (27), were also passively delivered to plaque monocytes and macrophages. Decreased uptake of 89Zr-labeled dextran nanoparticles after delivery of targeted small interfering RNA demonstrated the potential of this approach for vulnerable plaque detection and preemptive stabilization.

Of related interest, van der Valk et al. recently published results of a first-in-human trial of liposome-mediated delivery of the antiinflammatory drug prednisolone to atheromata (28). Although ex vivo analysis demonstrated successful liposomal delivery to plaque macrophages, no decreases in vessel permeability were detected with dynamic contrast-enhanced MR imaging and no localized antiinflammatory effects were detected with 18F-FDG PET/CT. Despite the lack of efficacy, this study importantly demonstrates the clinical feasibility of nanomedicinal delivery to atherosclerotic plaques and illustrates the potentially complementary roles of nanomedicine and advanced imaging in the clinical management of cardiovascular disease.

ADDITIONAL CARDIOVASCULAR APPLICATIONS OF INFLAMMATORY CELL IMAGING

Inflammatory cell imaging via radiolabeled nanoparticles has also been applied to other areas of diagnostic cardiovascular imaging research. Ueno et al. used PET/CT and passively targeted dextran-coated cross-linked iron oxide nanoparticles labeled with 64Cu to quantify myeloid cell infiltration in murine cardiac allografts and predict graft rejection and survival (Fig. 4) (29). The same laboratory also
used PET/CT imaging with passively targeted 18F-labeled cross-linked iron oxide nanoparticles to quantify aortic aneurysm macrophages in a murine model of aortic aneurysm (30). They were able to demonstrate in this pilot study that the magnitude of the macrophage-targeted PET/CT signal had predictive value for dimensional stability of aneurysms.

CONCLUSION

The diverse array of nanoparticulate imaging agents and theranostics described above illustrates the current utility of nanoparticles in cardiovascular imaging and therapy. These agents provide valuable insight into the molecular and cellular mechanisms of cardiovascular disease and illustrate both the limitations and the significant potential of nanoparticles in diagnostic and therapeutic applications. Further technologic development to improve performance, address safety concerns, and fulfill regulatory obligations is required for clinical translation of these emergent technologies.

DISCLOSURE

Dr. Stendahl is supported by NIH T32 training grant HL098069. No other potential conflict of interest relevant to this article was reported.

REFERENCES

Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 2: Radiolabeled Probes

John C. Stendahl and Albert J. Sinusas

Published online: August 20, 2015.
Doi: 10.2967/jnumed.115.164145

This article and updated information are available at:
http://jnm.snmjournals.org/content/56/11/1637

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml